Dissecting the cancer epigenome – fundamental lessons from developmental biology
This project aims to investigate the parallels between cancer epigenetics and early placental development to uncover novel regulatory mechanisms and their implications for disease.
Projectdetails
Introduction
DNA methylation is a tightly controlled mechanism that is essential for normal development and genome regulation. Although maintained in a highly static pattern across healthy tissues, DNA methylation is globally reprogrammed in nearly all malignant cancers, including gains at thousands of gene promoters and global loss across large domains.
Research Background
Substantial work from our group to characterize multiple primary tumor cohorts, transgenic animal models, and cancer cell lines finds that current experimental systems rarely, if ever, capture key features of the cancer epigenome.
Innovative Hypothesis
In contrast, our parallel efforts to understand epigenetic dynamics in development suggest an alternative, highly innovative hypothesis with a clear path for investigation. We find that the epigenetic alterations in cancer very closely mirror patterns that emerge in the early placenta, a tissue that naturally acquires invasive, immune suppressive, angiogenic, metabolically plastic, and mutationally tolerant properties.
Key Findings
Notably, this cancer-like epigenome depends on dynamic, previously undiscovered configurations of regulators that can be triggered without genetic mutation.
Methodology
With these insights, we have innovated tractable in vitro and in vivo platforms to dissect the biochemical, genetic, and physiological properties of this unique form of genome regulation as it supports developmental processes.
Future Directions
We believe these efforts will demonstrate that the placenta and, by extrapolation, the cancer epigenome reflect a switch-like reprogramming event that can be studied at high resolution.
Goals and Impact
In line with the ERC-ADG program’s goals, we will pursue ambitious and critical questions, resolve long-standing paradoxes, and provide a complete model of epigenetic transformation in development with direct disease implications.
Team and Resources
Our world-class interdisciplinary team, extensive preliminary data, experimental design, and proven track record will enable us to turn this grant into high-impact and translationally relevant discoveries.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.487.500 |
Totale projectbegroting | € 2.487.500 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and DiagnosisEpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors. | ERC Starting... | € 1.500.000 | 2024 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic RecurrenceThis project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes. | ERC Consolid... | € 1.995.582 | 2024 | Details |
Deciphering non-genetic determinants and targetability of cancer cell plasticity.This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment. | ERC Consolid... | € 2.000.000 | 2025 | Details |
Epigenetic profiling of menstrual blood for precision cancer detection and preventionThe EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers. | ERC Proof of... | € 150.000 | 2024 | Details |
Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis
EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence
This project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes.
Deciphering non-genetic determinants and targetability of cancer cell plasticity.
This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.
Epigenetic profiling of menstrual blood for precision cancer detection and prevention
The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.